폐렴구균 백신 시장 : 백신 유형, 연령층, 투여 경로, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Pneumococcal Vaccine Market is projected to grow by USD 21.67 billion at a CAGR of 8.18% by 2032.

Pneumococcal Vaccine Market Executive Summary

Pneumococcal vaccines remain a core public health and life sciences priority because Streptococcus pneumoniae causes invasive pneumococcal disease, pneumonia, meningitis, bacteremia, and otitis media across pediatric, adult, and immunocompromised populations. The World Health Organization recommends pneumococcal conjugate vaccines in childhood immunization programs, while the U.S. CDC continues to identify pneumococcal pneumonia as a major cause of adult hospitalization and severe disease among older adults and people with underlying medical conditions.

Market momentum is being shaped by broader-valent pneumococcal conjugate vaccines, adult immunization expansion, national immunization program updates, and rising attention to antimicrobial resistance. As countries evaluate PCV10, PCV13, PCV15, PCV20, PPSV23, and next-generation candidates, success increasingly depends on serotype coverage, real-world effectiveness, affordability, cold-chain execution, programmatic fit, and evidence-based policy adoption.

Transformative Shifts in the Pneumococcal Vaccine Landscape

The pneumococcal vaccine landscape is shifting from childhood-only protection toward life-course immunization. Pediatric programs remain foundational, but aging populations, chronic disease prevalence, and higher clinical risk among adults are elevating demand for adult pneumococcal vaccination. Broader-valent conjugate vaccines are changing competitive dynamics by targeting additional disease-causing serotypes and simplifying schedules in some markets.

Policy and procurement models are also evolving. High-income countries increasingly rely on advisory committee recommendations, real-world effectiveness data, pharmacoeconomic evidence, and post-authorization safety monitoring, while lower- and middle-income countries prioritize Gavi support, pooled procurement, supply reliability, and equitable access. At the same time, serotype replacement, antimicrobial resistance patterns, and regional differences in circulating strains are driving ongoing surveillance and vaccine portfolio diversification.

Cumulative Impact of Artificial Intelligence on Pneumococcal Vaccines

Artificial intelligence is accelerating pneumococcal vaccine development and commercialization by improving antigen selection, serotype surveillance, trial design, demand planning, and manufacturing quality control. AI-enabled genomic analytics can help monitor pneumococcal strain evolution and detect serotype replacement patterns faster than conventional manual approaches, strengthening evidence for vaccine updates and regional targeting.

Across commercialization and public health delivery, AI supports more accurate immunization demand planning, cold-chain risk prediction, adverse event signal detection, provider engagement, and prioritization of high-risk populations. For manufacturers, machine learning can improve yield monitoring, batch consistency, deviation detection, and process analytics in complex conjugate vaccine production. The cumulative impact is a more responsive pneumococcal vaccine ecosystem, though adoption must be governed by validated models, transparent data lineage, cybersecurity controls, privacy safeguards, and regulatory-grade documentation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding adult vaccination awareness, and policy modernization in countries such as China, India, Japan, Australia, and South Korea. National immunization decisions vary widely, making local serotype data, pricing, reimbursement design, and manufacturing partnerships central to market access. North America remains a mature and innovation-led region, supported by CDC and NACI guidance, strong pharmacy vaccination infrastructure, electronic immunization records, and rapid adoption of higher-valent adult pneumococcal vaccines.

Latin America benefits from established public immunization systems and PAHO-supported procurement mechanisms, with Brazil and Mexico acting as important demand centers for routine pediatric protection and risk-based adult vaccination. Europe is shaped by national immunization technical advisory groups, EMA-authorized products, health technology assessment, and differentiated adult recommendations across countries. The Middle East, particularly GCC markets, is investing in preventive care and adult immunization as part of healthcare modernization, while Africa remains heavily influenced by donor-supported pediatric vaccine access, cold-chain capacity, health workforce reach, and the need to reduce pneumonia mortality through sustained routine immunization coverage.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets present strong long-term potential as governments strengthen childhood immunization, expand private-sector vaccination, improve disease surveillance, and build regional healthcare capacity; however, affordability, procurement predictability, and cold-chain consistency remain critical. The GCC is moving toward prevention-focused healthcare strategies, creating opportunities for adult pneumococcal vaccination among older adults, people with diabetes, people with chronic respiratory or cardiovascular disease, and other high-risk groups.

The European Union offers a regulated, evidence-driven environment where health technology assessment, budget impact, pharmacovigilance, and serotype epidemiology influence adoption. BRICS countries represent scale and manufacturing opportunity, especially as China, India, and Brazil invest in domestic vaccine capabilities, public-sector immunization reach, and localized regulatory pathways. G7 markets remain primary centers for higher-valent vaccine uptake, real-world evidence generation, adult immunization policy development, and premium access pathways. NATO countries overlap significantly with high-income immunization systems, where pandemic preparedness, resilient supply chains, life-course vaccination, and adult vaccination infrastructure are increasingly strategic priorities.

Key Country Insights Across Major Pneumococcal Vaccine Markets

The United States is a leading pneumococcal vaccine market due to ACIP recommendations, broad retail pharmacy access, Medicare-linked adult vaccination pathways, and strong adult immunization infrastructure, while Canada follows NACI guidance with implementation shaped by provincial and territorial programs. Mexico and Brazil rely on large public immunization systems, with Brazil's national program and local production ecosystem supporting broad reach. In Europe, the United Kingdom, Germany, France, Italy, and Spain each apply national recommendations that differ by age, risk group, vaccine type, reimbursement approach, and public health budget priorities, while Russia maintains a sizeable immunization environment influenced by domestic policy, epidemiological priorities, and supply considerations.

China is expanding its vaccine ecosystem through growing private demand, regulatory modernization, adult prevention awareness, and domestic innovation, while India combines a large pediatric population with public-sector introduction, affordability requirements, and expanding immunization infrastructure. Japan has well-established elderly vaccination policies and a strong preventive healthcare culture, Australia maintains evidence-based national immunization scheduling and high-quality surveillance systems, and South Korea supports advanced vaccine access through strong healthcare infrastructure, high awareness of adult preventive care, and robust clinical adoption pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broader-valent conjugate vaccine strategies, robust adult immunization evidence, and differentiated market access plans by country income level, immunization schedule, procurement model, and policy environment. Investment in real-world effectiveness studies, serotype surveillance partnerships, pharmacoeconomic modeling, and post-introduction impact assessments will be essential to demonstrate value beyond pediatric disease prevention.

Manufacturers should strengthen supply resilience through diversified antigen sourcing, scalable conjugation capacity, cold-chain optimization, regional fill-finish partnerships, and quality-by-design manufacturing systems. Commercial and medical teams should align messaging with public health priorities, including antimicrobial resistance reduction, hospital burden mitigation, protection of high-risk adults, and improved routine immunization coverage. AI should be deployed in validated use cases such as demand forecasting, pharmacovigilance, genomic surveillance, and manufacturing analytics, with governance frameworks that meet regulatory, ethical, privacy, and cybersecurity expectations.

Research Methodology

This executive summary is built on secondary research from recognized public health authorities, regulatory agencies, immunization advisory bodies, peer-reviewed clinical literature, and market-facing vaccine policy sources. Core references include WHO pneumococcal vaccine position guidance, CDC and ACIP recommendations, NACI guidance, national immunization schedules, EMA and other regulatory information, and publicly available procurement and immunization program data.

The methodology emphasizes triangulation across epidemiology, vaccine technology, regulatory approvals, reimbursement pathways, public procurement models, adult immunization policy, pediatric schedule adoption, pharmacovigilance, and regional immunization infrastructure. Insights are validated through consistency checks across authoritative sources and are interpreted to support strategic decision-making without relying on unverified market-size, market-share, or forecasting claims.

Conclusion

The pneumococcal vaccine market is entering a new phase defined by higher-valent conjugate products, expanded adult vaccination, AI-enabled surveillance, and stronger evidence requirements for reimbursement and public procurement. Demand is supported by persistent pneumococcal disease burden, aging populations, risk-based vaccination policies, and the global need to reduce antibiotic use and prevent severe respiratory infections.

Organizations that combine scientific differentiation, reliable supply, country-specific access strategies, credible real-world evidence, and strong public health partnerships will be best positioned to capture growth opportunities. The most competitive participants will treat pneumococcal vaccination not only as a pediatric public health intervention but as a life-course prevention platform with measurable clinical, operational, and economic value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pneumococcal Vaccine Market, by Vaccine Type

• 7.1. Conjugate Vaccine
  • 7.1.1. Pcv13
  • 7.1.2. Pcv15
  • 7.1.3. Pcv20
• 7.2. Polysaccharide Vaccine

8. Pneumococcal Vaccine Market, by Age Group

• 8.1. Adult
• 8.2. Children
• 8.3. Geriatric

9. Pneumococcal Vaccine Market, by Route of Administration

• 9.1. Subcutaneous
• 9.2. Intramuscular

10. Pneumococcal Vaccine Market, by End User

• 10.1. Ambulatory Care Centers
• 10.2. Clinics
• 10.3. Hospitals
• 10.4. Immunization Centers

11. Pneumococcal Vaccine Market, by Distribution Channel

• 11.1. Offline
• 11.2. Online

12. Pneumococcal Vaccine Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Pneumococcal Vaccine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Astellas Pharma Inc.
• 16.3. Beijing Minhai Biotechnology Co., Ltd.
• 16.4. Bharat Biotech International Ltd.
• 16.5. Biological E. Limited
• 16.6. BioNTech SE
• 16.7. GSK plc
• 16.8. Inventprise LLC
• 16.9. KM Biologics Co., Ltd.
• 16.10. LG Chem Ltd.
• 16.11. Merck & Co., Inc.
• 16.12. Novartis AG
• 16.13. Panacea Biotec Ltd.
• 16.14. Pfizer Inc.
• 16.15. Pnuvax Incorporated
• 16.16. Sanofi S.A.
• 16.17. Serum Institute of India Pvt. Ltd.
• 16.18. Shenzhen Kangtai Biological Products Co., Ltd.
• 16.19. SK Bioscience Co., Ltd.
• 16.20. Vaxcyte Inc.
• 16.21. Walvax Biotechnology Co., Ltd.